Would you offer a patient with MMR-deficient colon cancer who underwent surgical resection of metachronous liver metastases "adjuvant therapy"?

In the general population of colorectal cancer patients with upfront resectable liver metastatic disease with low clinical risk, resection followed by a risk–benefit discussion regarding adjuvant chemotherapy or surveillance is appropriate. Fluorouracil-based chemotherapy compared to observation has...

Agree with the above excellent summary. I would discuss the last paragraph with the patient and would suggest the following if no trial is available:

1. If cDNA is negative, just observation and initiation of immunotherapy when demonstrable recurrence.
2. In the likely setting of positive ctDNA, offer Fo...